Dr Emily Sammons
BSc, MBChB, MSc
MRC PHRU Research Fellow
Dr Emily Sammons is a Clinical Research Fellow and DPhil student at the Clinical Trial Service Unit of the University of Oxford. She has particular research interests in diabetic eye disease and age-related macular degeneration. Alongside this she works on two large randomised controlled trials: ASCEND and REVEAL. ASCEND is studying whether aspirin and omega-3 fish oil supplementation protects against cardiovascular disease in people with diabetes. REVEAL is assessing the safety and benefits of taking a new lipid-modifying drug called anacetrapib, by those with pre-existing atherosclerotic vascular disease. Emily has background experience of working in General Medicine and a MSc in Public Health.
The Effects of Anacetrapib on Occlusive Vascular Events During Post-Trial Follow-Up of the REVEAL Randomized Trial
Sammons E. and Grp REVEALSC., (2019), CIRCULATION, 140, E971 - E971
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
ASCEND Study Collaborative Group None. et al, (2018), The New England journal of medicine, 16, 1529 - 1539
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
ASCEND Study Collaborative Group None., (2018), The New England journal of medicine
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Bowman L. et al, (2017), New England Journal of Medicine
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
Landray MJ. and REVEAL Collaborative Group None., (2017), American Heart Journal, 187, 182 - 190